Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milano, Italy.
Biomolecules. 2023 Jun 16;13(6):999. doi: 10.3390/biom13060999.
Emerging pharmacological strategies that target major virulence factors of antibiotic-resistant Mycobacterium tuberculosis (Mtb) are presented and discussed. This review is divided into three parts corresponding to structures and functions important for Mtb pathogenicity: the cell wall, the lipoarabinomannan, and the secretory proteins. Within the cell wall, we further focus on three biopolymeric sub-components: mycolic acids, arabinogalactan, and peptidoglycan. We present a comprehensive overview of drugs and drug candidates that target cell walls, envelopes, and secretory systems. An understanding at a molecular level of Mtb pathogenesis is provided, and potential future directions in therapeutic strategies are suggested to access new drugs to combat the growing global threat of antibiotic-resistant Mtb infection.
现有的针对抗药性结核分枝杆菌（Mycobacterium tuberculosis，Mtb）主要毒力因子的药理学策略被提出并加以讨论。本文综述分为三个部分，对应于与 Mtb 致病性相关的重要结构和功能：细胞壁、脂阿拉伯甘露聚糖和分泌蛋白。在细胞壁内，我们进一步关注三种生物聚合物亚组分：分枝菌酸、阿拉伯半乳聚糖和肽聚糖。本文综述了针对细胞壁、包膜和分泌系统的药物和药物候选物。本文提供了对 Mtb 发病机制的分子水平理解，并提出了潜在的治疗策略的未来方向，以获得新的药物来对抗日益严重的全球抗药性 Mtb 感染威胁。
